This is a database of the academic work published by our staff and students. The full text of many of our journal articles is available free of charge from this website. Older publications are currently available at https://publications.icr.ac.uk

  • Real-time intrafraction motion monitoring in external beam radiotherapy. 

    Bertholet, J; Knopf, A; Eiben, B; McClelland, J; Grimwood, A; Harris, E; Menten, M; Poulsen, P; Nguyen, DT; Keall, P; Oelfke, U (2019-08-07)
    Radiotherapy (RT) aims to deliver a spatially conformal dose of radiation to tumours while maximizing the dose sparing to healthy tissues. However, the internal patient anatomy is constantly moving due to respiratory, ...
  • Acquired genetic events and NF1 mutations in advanced breast cancer 

    Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, M; Kingston, B; O'Leary, B; Herrera-Abreu, M; Cutts, R; Garcia-Murillas, I; Bye, H; Walker, B; Gonzalez, D; Yuan, L; Jamal, S; Hubank, M; Lopez-Knowles, E; Schuster, E; Dowsett, M; Osin, P; Nerurkar, A; Parton, M; Okines, A; Johnston, S; Ring, A; Turner, N
  • Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. 

    Loriot, Y; Necchi, A; Park, SH; Garcia-Donas, J; Huddart, R; Burgess, E; Fleming, M; Rezazadeh, A; Mellado, B; Varlamov, S; Joshi, M; Duran, I; Tagawa, ST; Zakharia, Y; Zhong, B; Stuyckens, K; Santiago-Walker, A; De Porre, P; O'Hagan, A; Avadhani, A; Siefker-Radtke, AO; BLC2001 Study Group (2019-07-25)
    BACKGROUND: Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase ...
  • Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial. 

    Hrebien, S; Citi, V; Garcia-Murillas, I; Cutts, R; Fenwick, K; Kozarewa, I; McEwen, R; Ratnayake, J; Maudsley, R; Carr, TH; de Bruin, EC; Schiavon, G; Oliveira, M; Turner, NC (2019-03-12)
    BACKGROUND: Dynamic changes in circulating tumour DNA (ctDNA) levels may predict long-term outcome. We utilised samples from a phase I/II randomised trial (BEECH) to assess ctDNA dynamics as a surrogate for progression ...
  • Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk. 

    Wu, L; Shu, X; Bao, J; Guo, X; CRUK, BPC3, CAPS, PEGASUS consortia PRACTICAL; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W (2019-07-23)
    Several blood protein biomarkers have been associated with prostate cancer (PrCa) risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein ...

View more